To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC81249 | PC6-VC-PAB-MMAE |
PC6-VC-PAB-MMAE is a Drug-Linker Conjugates for ADC. PC6-VC-PAB-MMAE consists of the ADC Cytotoxin MMAE and a linker. PC6-VC-PAB-MMAE can be used for synthesis of ADCs.
More description
|
|
| DC81248 | PB2-IN-3 |
PB2-IN-3 (Compound 11) is a PB2 inhibitor. PB2-IN-3 exhibits antiviral activity against Influenza A H1N1 and H3N2 strains. PB2-IN-3 can be used in studies related to influenza A virus infection.
More description
|
|
| DC81243 | PARP1-IN-55 |
PARP1-IN-55 is a potent and selective PARP1 inhibitor with an IC50 value of 0.019 μM. PARP1-IN-55 exhibits anti-proliferative selective activity against MCF-7 breast cancer cells (IC50 = 3.6 μM). PARP1-IN-55 inhibits the PARP1-mediated DNA damage repair pathway, induces ROS accumulation, disrupts mitochondrial membrane potential, induced apoptosis and suppresses cancer cell migration, invasion, and colony formation. PARP1-IN-55 can be used for the study of breast cancer.
More description
|
|
| DC81240 | PARP1-IN-50 |
PARP1-IN-50 is a selective and orally active PARP-1 inhibitor with an IC50 of 64.98 nM. PARP1-IN-50 can inhibit PAR formation and induce DNA double strand breaks, thereby causing DNA damage. PARP1-IN-50 can induce G2/M phase arrest and cancer cells apoptosis. PARP1-IN-50 demonstrates significant antiproliferative activity against various cancer cells. PARP1-IN-50 can be used for the research of cancer, such as breast cancer.
More description
|
|
| DC81238 | PARP1-IN-47 |
PARP1-IN-47 (Compound 35) is a highly selective PARP1 inhibitor (IC50 <100 nM). PARP1-IN-47 blocks poly(ADP-ribosyl)ation and disrupts DNA damage repair pathways to induce tumor cell apoptosis. PARP1-IN-47 is promising for research of solid tumors and hematological malignancies.
More description
|
|
| DC81228 | p53-Y220C/PLK1 modulator-1 |
p53-Y220C/PLK1 modulator-1 (compound15) is a dual modulator targeting p53-Y220C and PLK1. p53-Y220C/PLK1 modulator-1 can be used in the cancer.
More description
|
|
| DC81219 | OZD-MET 01 |
OZD-MET 01 is a chaperone-med iatedprotein PROTAC-type MET degrader. OZD-MET 01 can inhibit proliferation of H596 and H1437 cells with IC50 values of 3.07 and 3.5 μM. OZD-MET 01 can be used for the research of cancer, such as non-small cell lung cancer. (Structure Note: Pink: MET ligand; Blue: chaperone ligand; MET ligand-Linker:)
More description
|
|
| DC81218 | Oxazole-4-carboxylic acid |
Oxazole-4-carboxylic acid (1,3-Oxazole-4-carboxylic acid) is a metal-organic framework (MOF).
More description
|
|
| DC81217 | OV329 hydrochloride |
OV329 hydrochloride is a potent GABA aminotransferase inactivator. OV329 hydrochloride is a Vigabatrin analogue. OV329 hydrochloride can increase brain GABA levels and block abnormal intracerebral hyperexcitability. OV329 hydrochloride exhibits anticonvulsant and antiepileptic activities. OV329 hydrochloride can be used for the research of neurological disease, such as seizure.
More description
|
|
| DC81216 | OTOP1-IN-1 |
OTOP1-IN-1 (compound C2.2) is a potent zebrafish Otopetrin 1 (OTOP1) inhibitor with an IC50 of 6.67 µM. OTOP1-IN-1 exhibits selectivity for zebrafish OTOP1 over mOTOP1 and hOTOP1.
More description
|
|
| DC81213 | Osaterone acetate |
Osaterone acetate is an orally active steroid anti-androgen agent, mainly used for benign prostatic hyperplasia (BPH) in dogs. Osaterone acetate competitively antagonizes androgen receptor and inhibits 5α-reductase, reducing the concentration of dihydrotestosterone (DHT) while blocking the growth-stimulating effects of testosterone and DHT on prostate cells. Osaterone acetate can rapidly alleviate the symptoms of BPH in dogs without affecting the fertility of breeding dogs.
More description
|
|
| DC81212 | ortho-Topolin riboside |
ortho-Topolin riboside is a naturally occurring cytokinin secreted from Populus x robusta leaves after sunrise. ortho-Topolin riboside has shown unique cytotoxic activity against NCI60 cell lines compared with the activity of other cytokinins.ortho-Topolin riboside induced differentiation through inhibition of STAT3 signaling in acute myeloid leukemia HL-60 cells.
More description
|
|
| DC81211 | ORG-25435 |
ORG-25435 is an alpha amino acid phenolic ester derivative. ORG-25435 has intravenous anesthesia activity. ORG-25435 can be used for anesthesia related research.
More description
|
|
| DC81210 | Org 20599 methanesulfonate |
Org20599 methanesulfonate is a direct agonist of the GABAA receptor with an EC50 of 1.1 μM. Org20599 methanesulfonate can be used in the research of neurological disorders.
More description
|
|
| DC81209 | Orexin receptor antagonist 6 |
Orexin receptor antagonist 6 (Compound 72) is a selective orexin 1 receptor (OX1) antagonist with a Ke of 8.5 nM and > 1180-fold selectivity for OX2. Orexin receptor antagonist 6 does not produce its own conditioned place preference (CPP) or aversive effects, and can inhibit the formation of CPP induced by psychoactive substances. Orexin receptor antagonist 6 can be used for research of neurological disease.
More description
|
|
| DC81207 | OPC-18750 |
OPC-18750 is a novel positive inotropic agent and 2(lH)-quinolinone derivative. OPC-18750 displays positive inotropic and coronary vasodilating effects.
More description
|
|
| DC81206 | Opc-15161 |
Opc-15161 is a novel superoxide generation inhibitor and major degradation product of OPC-15160.
More description
|
|
| DC81204 | OP-1690 |
OP-1690 is a complete estrogen receptor (ERα) antagonist (CERAN), with pIC50 values of 7.5 and 7.9 in alkaline phosphatase (AP) activity assay and TR-FRET assay, respectively. OP-1690 modulates receptor function by inducing ERα tetramerization, effectively induces ERα degradation, inhibits target gene transcription, but exhibits low antiproliferative potency. OP-1690 can be used for breast cancer research.
More description
|
|
| DC81198 | Oltipraz metabolite M2 |
Oltipraz metabolite M2, an active metabolite of Oltipraz, is an orally active HIF-1α inhibitor. Oltipraz metabolite M2 increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK in high-fat diet (HFD)-fed mice. Oltipraz metabolite M2 can be used for hepatic steatosis and steatohepatitis research.
More description
|
|
| DC81184 | NSP-DMAE-HEG-Giu-NHS |
NSP-DMAE-HEG-Giu-NHS (Fig.18) is an activated labeling reagent containing acridine ester, and it is a key component of Cyclosporine A tracers.
More description
|
|
| DC81180 | NSC127916 |
NSC127916 (compound Ib) is a 2,6-diaminopurine analogue of Methotrexate.
More description
|
|
| DC81175 | NS8593 |
NS8593 is an SK channel (small conductance Ca2+-activated K+ channels) inhibitor. NS8593 reversibly inhibited recombinant SK3-mediated currents (human SK3 and rat SK3). NS8593 inhibits all the SK1-3 subtypes Ca2+-dependently (Kd = 0.42, 0.60, and 0.73 μM, respectively, at 0.5 μM Ca2+). NS8593 does not affect the Ca2+-activated K channels of intermediate and large conductance (hlk and hBK channels, respectively). NS8593 can also inhibit TRPM7 (melastatin-related TRP cation channel 7) (IC50 = 1.6 mM). NS8593 can be used for the study of central nervous system (CNS) related diseases.
More description
|
|
| DC81171 | NPFFR2 modulator-1 |
NPFFR2 modulator-1 (compound 11) is a NPFFR2 modulator.
More description
|
|
| DC81168 | North-methanocarbathymidine |
North-methanocarbathymidine (N-MCT) is a potent antiviral agent. North-methanocarbathymidine inhibits DNA synthesis. North-methanocarbathymidine demonstrates potent antiviral activity against HSV-1, HSV-2 and KSHV. North-methanocarbathymidine exhibits anticancer activity against colon adenocarcinoma expressing HSV-tk.
More description
|
|
| DC81167 | Norhyodeoxycholic acid |
Norhyodeoxycholic acid (NHDCA) is a synthetic bile acid and a derivative of hyodeoxycholic acid (HDCA).
More description
|
|
| DC81162 | NMDAR blocker 1 |
NMDAR blocker 1 is an NMDA receptor channel blocker with an IC50 of 5.0 μM. NMDAR blocker 1 exhibits fast on-off blockade kinetics and strong voltage dependence, and does not compete with glutamate or glycine. NMDAR blocker 1 prevents glutamate/NMDA-induced intracellular Ca2+ overload, modulates the glutamate-nitric oxide-cGMP pathway. NMDAR blocker 1 prevents in vitro excitotoxic neurodegeneration of cultured cerebellar and hippocampal neurons. NMDAR blocker 1 attenuates excitotoxic insult in an mouse model of hyperammonemia-induced excitotoxicity. NMDAR blocker 1 can be used for the research of neurodegenerative diseases.
More description
|
|
| DC81161 | NLX-219 |
NLX-219 is a selective agonist of the 5-HT1A with a pKi of 10.21. NLX-219 activates ERK1/2 phosphorylation, inhibits adenylyl cyclase activity, promotes β-arrestin recruitment. NLX-219 can be used for the research of neurological disease.
More description
|
|
| DC81159 | NLRP3-IN-87 |
NLRP3-IN-87 is a selective and orally active NLRP3 inhibitor with a Kd of 0.23 μM. NLRP3-IN-87 binds directly to the NLRP3 NACHT domain, disrupts NLRP3-NEK7 and NLRP3-ASC interactions, inhibits ASC oligomerization, and blocks inflammasome assembly. NLRP3-IN-87 suppresses caspase-1 activation and IL-1β secretion. NLRP3-IN-87 exhibits anti-inflammatory and analgesic activity, reducing joint swelling, inflammation, and pain in an MSU-induced acute gout mouse model. NLRP3-IN-87 can be used for the research of gout.
More description
|
|
| DC81157 | NLRP3 modulator 7 |
NLRP3 modulator 7 (Compound 17B) is a NLRP3 inflammasome regulator. NLRP3 modulator 7 has inhibitory activity against IL-1b, and its IC50 is less than 500 nM.
More description
|
|
| DC81151 | NHS-Phosphine |
NHS-Phosphine is an amine-reactive compound that can be used to derivatize primary amines of proteins or amine-coated polymer surfaces for ligation to azide-tagged molecules.
More description
|
|